openPR Logo
Press release

Lymphoblastic Lymphoma Market Trends and Forecast by 2016 - 2024

06-26-2017 03:48 PM CET | Health & Medicine

Press release from: TMR - Healthcare

Lymphoblastic Lymphoma Market Trends and Forecast by 2016 - 2024

Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other areas, stem cell transplantation, and steroids. Lymphoblastic lymphoma is a rare and aggressive form of non-Hodgkin lymphoma; however, it can be cured with 80% to 90% survival rates in children with intensive therapy for early stages (I & II), while 80% survival rates in more advanced stages of lymphoblastic lymphoma (stage III & IV).

Obtain Report Details @
http://www.transparencymarketresearch.com/lymphoblastic-lymphoma-market.html

Lymphoblastic lymphoma is an aggressive form of non-Hodgkin lymphoma; however, it is relatively rare form affecting an estimated 2% patients of all non-Hodgkin lymphoma patients. Lymphoblastic lymphoma primarily affects teenagers or adults in their early 20s, and occurs more frequently in males than females. Lymphoblastic lymphoma arises most commonly from T-cells / t-lymphocytes, and is predominantly a lymph node-based disease, affecting the lymphatic system. The clinical distinction of the diseases - lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ACL) - vary according to different institutions and studies. However, recently, the World Health Organization (WHO) stated that the characteristics of lymphoblastic lymphoma and acute lymphoblastic leukemia are similar at all levels genetically, morphologicallym, and phenotypically as well. Hence, it has unified these diseases as precursors of T-cells / B-cells lymphoblastic lymphoma/leukemia.

Rising incidence combined with increasing prevalence of cancer across the world is the major factor expected to drive the global lymphoblastic lymphoma market during the forecast period from 2016 to 2024. Additionally, increasing prevalence of genetic diseases and technological advancements in the field of diagnostics is expected to augment the global lymphoblastic lymphoma market. According to the American Cancer Society, as on January 1, 2016, there were an estimated 686,390 non-Hodgkin lymphoma cancer survivors in the U.S., out of which around 13,727 patients were lymphoblastic lymphoma survivors. Surveillance studies of the American Cancer Society also indicate that the total number of all types of cancer survivors is expected to reach 20.3 million patients by 2026, out of which people suffering from non-Hodgkin lymphoma is expected to reach 925,150. This increasing incidence and prevalence rate is expected to drive the global lymphoblastic lymphoma market from 2016 to 2024.

In terms of region, the global lymphoblastic lymphoma market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global lymphoblastic lymphoma market in 2015 due to increasing prevalence of cancer especially non-Hodgkin lymphoma, along with advanced diagnostic instruments and technologies, increasing health care expenditure, and rising patient demand for better health care facilities. Increasing focus on targeted drugs for diseases and rising prevalence of cancer is likely to drive the market in Europe. The global lymphoblastic lymphoma market in Asia Pacific is expected to register highest CAGR during the forecast period from 2016 to 2024. Rising genetic diseases and increasing incidence of non-Hodgkin lymphoma in countries in Asia Pacific such as China and India are expected to drive the global lymphoblastic lymphoma market in the region from 2016 to 2024.

Key players in this market are Novartis AG, Sanofi SA, Pfizer, Inc., Bristol-Myers Squibb Company, Jazz Pharmaceuticals plc, AstraZeneca, Eisai, Inc., Amgen, Inc., and BioCryst Pharmaceuticals, Inc. Key players in the research and development are the National Cancer Institute, the University of Texas MD Anderson Cancer Center, the Fred Hutchinson Cancer Research Center, the Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital, and the Johann Wolfgang Goethe University Hospitals, and others.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2924

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lymphoblastic Lymphoma Market Trends and Forecast by 2016 - 2024 here

News-ID: 596325 • Views:

More Releases from TMR - Healthcare

Clinical Trial Management System (CTMS) Market : Projection of Each Major Segment over the Forecast Period
Clinical Trial Management System (CTMS) Market : Projection of Each Major Segmen …
With companies long having realized that the best way to remain competitive in the pharmaceutical industry is by ploughing back of profits into R&D projects, the demand for clinical trial management systems is expected to see an uptick. While this will help impel the market greatly in the coming years, what also needs to be taken into consideration that the cost of implementing such a system may deter investment decisions. The
Electronic Health Records Market : Industry Analysis and Detailed Profiles of to …
The global market for electronic health record (EHR) features a largely fragmented vendor landscape, with the presence of a large number of small and large players and the top five companies cumulatively accounting for a nearly 44% of the overall market in 2016. Leading vendors in the global EHR market are adopting inorganic growth strategies such as mergers and acquisitions to expand their reach across high-growth potential regional markets, consolidate
Fuel Oil Market Intelligence Report Offers Growth Prospects
Fuel Oil Market Intelligence Report Offers Growth Prospects
The global transportation industry has been growing at a significant pace since the past decade. Companies operating in the transportation industry are the largest consumers of the fuel oil. Apart from this, fuel oil also finds application in the petrochemical industry and petroleum refineries. The building materials industry is also on the rise since many years. The demand for fuel oil is expected to increase from the building materials industry.
Thermoset Resin Market Global Industry Analysis, Trends and Forecast, 2016 - 2024
Thermoset Resin Market Global Industry Analysis, Trends and Forecast, 2016 - 202 …
The global composite industry has been expanding significantly in terms of production, technological advancements, and developments. Thermoset resin plays a vital role in the composite industry. Thermoset resins are used extensively in the manufacture of composites; these resins are employed in the fabrication of products for end-use industries such as aerospace, automotive, sporting goods, construction, electronics, and wind energy. The thermoset resin market can be segmented into six resin types:

All 5 Releases


More Releases for Lymphoblastic

Global Acute Lymphoblastic Leukemia Drug Market Overview | 2034
The Expert Market Research report presents an in-depth analysis of the global acute lymphoblastic leukemia (ALL) therapeutics market, highlighting a landscape shaped by advanced treatment modalities, increasing research funding, and the rising burden of leukemia cases across major global regions. With novel immunotherapies and targeted drugs entering clinical practice, the market is on a robust growth trajectory. Acute Lymphoblastic Leukemia Therapeutics Market Size The acute lymphoblastic leukemia (ALL) therapeutics market was valued
Acute Lymphoblastic Leukemia Therapeutics Market Size, Growth & Forecast 2025-20 …
The Acute Lymphoblastic Leukemia Therapeutics Market Is Set To Grow At An Estimated CAGR Of 8.5% From 2025 To 2034, Rising From $12 Billion In 2024 To $27.4 Billion By 2034. On April 16, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Acute Lymphoblastic Leukemia Therapeutics market goods. The market study excludes key regions that are
Acute Lymphoblastic Leukemia (ALL) Therapeutics Market: An Overview
Acute Lymphoblastic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow, characterized by an overproduction of immature white blood cells known as lymphoblasts. ALL can occur in both children and adults, with its peak incidence in children aged 2 to 5 years. This disease, due to its aggressive nature, requires immediate medical intervention and treatment, often involving chemotherapy, radiation, and in some cases, stem cell
Acute Lymphoblastic Leukemia Market: Trends and Forecast -2031
The global acute lymphoblastic leukemia (ALL) market is witnessing substantial growth, driven by factors such as increased awareness, early detection, and advancements in treatment options. This article provides a comprehensive overview of the market dynamics, including key insights, trends, and forecasts for the period 2022-2031. The global acute lymphoblastic leukemia market was valued at US$ 2.2 billion in 2021, with a projected CAGR of 7.6% from 2022 to 2031. By the
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Acute Lymphoblastic Leukemia Market Size & Growth Analysis Report, 2021-2027
The global acute lymphoblastic leukemia market is growing at a significant CAGR during the forecast period. One of the major factors that are driving the global acute lymphoblastic leukemia market is the growing number of patients of acute lymphoblastic leukemia. According to the Leukemia & Lymphoma Society, approximately every 3 minutes one person in the United States (US) is diagnosed with blood cancer. Further, an estimated combined total of 176,200